PD-L1 and checkpoint inhibitors have been front and center in the media relating to the treatment of cancer. Researches are now looking at the association with diabetes and metabolic disease.
| less than a minute read
Checkpoint Inhibitors and Diabetes
Get in touch
Get in touch
In patients with Type 1 diabetes, T cells in the immune system mistakenly attack islet cells in the pancreas that make insulin. Scientists at Boston Children’s Hospital have come up with a way to thwart this wayward autoimmune reaction, and it involves a protein that plays a prominent role in new immunotherapy treatments for cancer: PD-L1.
Get in touch
Get in touch
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-03-19-17-30-27-593-65f9cbb3bf22b75d160b136f.jpg)
Welcome to ‘What every Life Sciences lawyer needs (Commercial Contracts)’, a series in which DLA Piper’s Life Sciences Commercial...
/Passle/596df0e43d947619ec025f26/MediaLibrary/Images/2024-04-25-12-46-49-709-662a50b99766bc4f3d58967f.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-04-22-08-46-05-640-662623cd0532c9880e85e938.jpg)
/Passle/596df0e43d947619ec025f26/SearchServiceImages/2024-04-18-09-16-42-370-6620e4fa7330266071d4ac1d.jpg)
/Passle/596df0e43d947619ec025f26/MediaLibrary/Document/2024-04-15-09-40-05-618-LS_marzec_2024_EN_thumbnail_1.png)
